Eagle Pharmaceuticals

238 articles with Eagle Pharmaceuticals

• Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint

  6/9/2022

  Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection BARHEMSYS ® (amisulpride for injection) and BYFAVO ® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 billion per year 1 addressable market and projected annual peak sales of $275 2 million in the U.S.

• Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker

  6/1/2022

  Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker.

• Eagle Pharmaceuticals to Present at the William Blair 42nd Annual Growth Stock Conference

  5/26/2022

  Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growth Stock Conference.

• Eagle Pharmaceuticals Reports First Quarter 2022 Results

  5/9/2022

  Eagle Pharmaceuticals, Inc. announced financial results for the three months ended March 31, 2022.

• Eagle Pharmaceuticals to Host First Quarter 2022 Financial Results on May 9, 2022

  4/28/2022

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens.

• Eagle Pharmaceuticals Agrees to Terms to Acquire Acacia Pharma Group plc

  3/28/2022

  Eagle Pharmaceuticals, Inc. announced it has reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia Pharma Group plc to Eagle by way of a scheme of arrangement under Part 26 of the United Kingdom’s Companies Act 2006.

• 

  Eagle Announces Acquisition of Acacia in Strategic Good Fit

  3/28/2022

  New Jersey-based Eagle Pharmaceuticals, a company geared towards pharmaceutical hospital sales, has finalized terms to acquire Acacia Pharma Group, PLC.

• Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results

  3/7/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2021.

• Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022

  2/24/2022

  Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2021 fourth quarter and full year financial results on Monday, March 7, 2022, before the market opens.

• Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™

  2/1/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its novel product PEMFEXY™ (pemetrexed for injection).

• Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker

  1/31/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group, (“AOP Health”), with whom it entered into a licensing agreement in August 2021, has engaged with the U.S. Food and Drug Administration (“FDA”) to obtain alignment on the content and format of the pre-clinical and clinical data required to support a new drug application (“NDA”) seeking approval of Landiolol.

• Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin

  1/18/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict with 180 days of marketing exclusivity.

• Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin

  1/5/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update for 2022:

• Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/3/2022

  Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference as follows.

• Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin

  12/29/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application (“ANDA”) for vasopressin.

• Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

  12/20/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.

• Eagle Pharmaceuticals Receives FDA Approval for Vasopressin

  12/15/2021

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new drug application (“ANDA”) for vasopressin.

• Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

  11/22/2021

  Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

• Eagle Pharmaceuticals Reports Third Quarter 2021 Results

  11/9/2021

  Eagle Pharmaceuticals Reports Third Quarter 2021 Results

• Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021

  10/28/2021

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens.